This is in line with the well-documented regulatory role of TGF-β in NK cell activation that emerged from several studies [32,76] supporting the development in NB of preclinical [77] and clinical studies with combining immunotherapies including the block of the TGF-β activity. The gene discussed is TGFB1; the disease is neuroblastoma.